This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-13.
Status change: Not Yet Recruiting → Recruiting2025-09-01